AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 14:33:37 17/06/2024 BST 5-day change 1st Jan Change
12,452 GBX -0.46% Intraday chart for AstraZeneca PLC -1.13% +17.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer MT
AstraZeneca: positive phase 3 results in lymphoma CF
AstraZeneca's Blood Cancer Combination Therapy Meets Primary Goal in Late-Stage Study MT
London stocks rebound ahead of key Economic data Our Logo
Astra's Imfinzi plus chemo approved for cancer form in US AN
AstraZeneca: Imfinzi approved in endometrial cancer CF
Astra gets US drug approval; Ascential trades in line AN
AstraZeneca Gains US FDA Approval for Endometrial Cancer Treatment MT
UK Stocks-Factors to watch on June 17 RE
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer DJ
AstraZeneca gets positive cancer test results for Calquence AN
AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer RE
AstraZeneca's Calquence Combo Extends Progression-free Survival in Mantle Cell Lymphoma Study MT
AstraZeneca Announces CALQUENCE (Acalabrutinib) Plus Chemoimmunotherapy Reduced the Risk of Disease Progression or Death by 27% Vs. Standard of Care in Patients with Untreated Mantle Cell Lymphoma in Echo Phase III Trial CI
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading MT
Tesla, Inc. : Musk moves a step closer to the $56 billion prize and the transfer of Tesla's headquarters to Texas Our Logo
AstraZeneca: Farxiga approved for diabetes as of age 10 CF
AstraZeneca's Type-2 Diabetes Drug Wins Pediatric Approval in US MT
US Food and Drug Administration Approves AstraZeneca?s FARXIGA in the US for the Treatment of Pediatric Type-2 Diabetes CI
AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S. DJ
AstraZeneca Gets FDA Approval for Pediatric Type-2 Diabetes Control Drug MT
AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes AN
European Equities Close Lower in Monday Trading Following Far Right Gains in EU Elections MT
UK Stocks Join Europe Retreat Ahead of US Fed Rate Decision MT
ASTRAZENECA : Berenberg raises its price target CF
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6 USD
Average target price
174.4 USD
Spread / Average Target
+9.95%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. European Equities Close Lower in Tuesday Trading; AstraZeneca Targets $80 Billion in Revenue by 2030
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW